Education, Research & Positions
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial Summary The SAGC trial, a randomized phase 2 study, investigated the efficacy of sintilimab (a PD-1 inhibitor) and anlotinib (Read More
